At a glance

What is ipamorelin?

Ipamorelin is an experimental five-amino acid peptide that acts as a ghrelin mimic, developed years ago under the code NNC 26-0161 but never marketed as a drug. It is sold through wellness and "research peptide" channels and promoted for recovery, body composition, and sleep, often paired with a GHRH analog such as CJC-1295 or sermorelin.

How does it work?

Ipamorelin activates the growth hormone secretagogue receptor, the same receptor the hunger hormone ghrelin¹ uses, which triggers the pituitary to release growth hormone in pulses. In laboratory work it is described as relatively "selective," raising growth hormone with comparatively little effect on other hormones such as cortisol and prolactin. In conscious swine, it released GH without raising ACTH or cortisol², while GHRP-6 and GHRP-2 raised both.

Because growth hormone and GHRH signaling act together, ghrelin-mimic peptides are often combined with GHRH analogs. No published human randomized controlled trial tests ipamorelin with CJC-1295 as of September 2026. The marketed benefits are extrapolated from this growth-hormone effect. This describes the proposed mechanism, separate from proven outcomes.

Is it FDA-approved?

No. Ipamorelin is not approved by the FDA and never reached market as a drug. Its compounding and sport status:

• Not eligible for routine 503A compounding, because its 503A nomination was withdrawn
• Still on FDA's 503B Category 2 list
• Prohibited at all times in sport under the WADA list, which covers growth hormone secretagogues including ipamorelin

What does the research show?

The human evidence is short pharmacology, not outcomes, and the supporting bone and gut data come from animal models:

Clinical development for post-operative ileus did not produce an approved product, and there are no controlled human trials supporting the marketed recovery or body-composition uses.

Frequently asked questions

Is ipamorelin FDA-approved?

No. Ipamorelin has never been FDA-approved for any human therapeutic indication. In a Phase 2 trial for postoperative ileus, ipamorelin showed no significant difference from placebo⁷ on the key efficacy endpoint, and clinical development did not produce an approved product. Ipamorelin has not undergone the Phase 3 trials required for FDA approval.

Is ipamorelin legal in the United States?

Ipamorelin's 503A nomination was withdrawn after it had been placed in Category 2, and FDA now lists it among bulk drug substances nominated but withdrawn⁸. As of September 2026, ipamorelin is not eligible for compounding under Section 503A, so it cannot be legally used in 503A compounded medications for human administration. Products sold online as ipamorelin are not regulated and do not have a legal pathway to human use in the United States.

Can a doctor prescribe ipamorelin?

Not in any way that can be lawfully filled in the United States under current regulations. Ipamorelin is not eligible for 503A compounding and remains on FDA's 503B Category 2 list, so no compounded preparation for human use is lawful. There is no FDA-approved manufactured form of ipamorelin to prescribe. Any product available online falls outside the regulated pharmaceutical supply chain.

What changed in the FDA peptide category list, and how does it affect ipamorelin?

The FDA's Section 503A bulk drug substance review process evaluates whether specific compounds may be used in compounded medications. Ipamorelin had been on the 503A Category 2 list, which removed the legal pathway that let compounding pharmacies prepare and dispense it under physician prescription. Its 503A nomination was later withdrawn, and FDA now lists it among substances nominated but withdrawn⁸, a step that was not a finding that it is safe. Ipamorelin was already off 503A Category 2 before April 2026, when FDA moved a group of other peptides, such as BPC-157, to that list. Withdrawal did not restore compounding eligibility: a withdrawn substance is not eligible for 503A compounding unless FDA adds it to the 503A bulks list or places it in Category 1, and ipamorelin remains on FDA's 503B Category 2 list.

What is the difference between ipamorelin and sermorelin?

Ipamorelin is a GHS-R1a agonist that mimics ghrelin at its receptor. Sermorelin is a GHRH analog that activates the GHRH receptor. Both ultimately stimulate GH release from the pituitary, but through different receptor pathways with different regulatory inputs. In studies of the growth-hormone-releasing peptide class, not ipamorelin itself, somatostatin only blunted their effect but nearly abolished GHRH's⁹.

What is the difference between ipamorelin and GHRP-2 or GHRP-6?

The primary distinction is hormonal selectivity. In swine, ipamorelin released GH without significantly raising ACTH or cortisol², while GHRP-2 and GHRP-6 raised both. In healthy adults, GHRP-2 and hexarelin also raised prolactin, ACTH, and cortisol¹⁰ alongside GH. GHRP-2 and GHRP-6 sit in FDA's Category 3 for 503A compounding¹¹.

Is ipamorelin prohibited in sport?

Yes. As of the 2026 WADA Prohibited List, ipamorelin is prohibited under category S2 (peptide hormones, growth factors, related substances, and mimetics), both in- and out-of-competition. Detection methodology in urine has been validated¹². Athletes subject to WADA or USADA jurisdiction who use ipamorelin risk anti-doping rule violations.

More for bones & muscles